表紙
市場調査レポート

セラノスティックスにおけるナノマテリアル:世界市場

Nanomaterials in Theranostics: Global Markets

発行 BCC Research 商品コード 275348
出版日 ページ情報 英文 170 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
セラノスティックスにおけるナノマテリアル:世界市場 Nanomaterials in Theranostics: Global Markets
出版日: 2013年07月05日 ページ情報: 英文 170 Pages
概要

世界におけるセラノスティックス用途ナノマテリアルの市場は、今後CAGR10.8%で推移し、2017年に1,870億米ドル以上に達すると予測されています。

当レポートでは、世界のセラノスティックス用途ナノマテリアル市場について調査し、世界市場の概要、市場実績と予測およびCAGR予測を含めた世界市場の分析、ナノスケールのマテリアルのメリット、癌・免疫不全・心血管・神経疾患におけるセラノスティックスの役割、治療薬(金ベース・磁性・高分子・シリカベース・カーボン・複合材料・リポソームナノマテリアル)の種類の特定、特許分析および主要企業のプロファイルなどをまとめ、概略下記の構成でお届けいたします。

第1章 イントロダクション

第2章 サマリー

第3章 概要

  • セラノスティックスおよびオーダーメイド医療の概要
  • ナノ粒子
    • パッシブ標的
    • アクティブ標的
  • ナノテクノロジー概要
    • 市販のナノテクノロジー製品
    • サイズの定義
    • 形状
    • 表面積
    • 量子ドット
    • カーボンナノチューブ
    • 多機能ナノマテリアル
  • ナノセラノスティックス概要
    • 金ベースのナノマテリアル
    • 磁性ナノマテリアル
    • 高分子ナノマテリアル
    • シリカベースのナノマテリアル
    • カーボンナノマテリアル
    • 複合材料ナノマテリアル
    • 生物学的ナノマテリアル
    • その他のナノマテリアル
    • ドラッグデリバリー

第4章 世界のナノマテリアルセラノスティックス市場

  • 世界のセラノスティックス市場におけるモノクロナール抗体
  • 世界の診断画像システムにおけるナノ粒子収益
  • 世界の創薬・調剤収益
  • 世界のMRI試薬収益
  • 世界の体外光学画像試薬市場
  • 世界のナノキャリア用途金ベース材料市場
  • 世界のナノキャリア用途リポソームベース材料市場
  • 世界のナノ結晶薬剤市場
  • 世界のベストセラー抗体薬市場

第5章 ナノセラノスティックドラッグデリバリー

  • イントロダクション
  • 体内薬剤放出研究
  • 薬剤効能
  • 将来の方向性

第6章 ナノマテリアル構造、特徴および調製方法

  • カーボンナノチューブ
  • フラーレンC60
  • タンパク質
  • セラノスティックスにおけるナノマテリアル
  • 金ナノ粒子
  • 磁性ナノ粒子
  • リポソーム
  • ナノ結晶
  • 量子ドット
  • 多機能ナノ粒子
  • 腫瘍画像・治療における量子ドット
  • 腫瘍画像・治療向け多機能磁性ナノ粒子
  • MRI・遺伝子デリバリー向け磁性ナノ粒子
  • 腫瘍画像・治療向け多機能磁性高分子ナノハイブリッド
  • 光熱治療向け金ナノマテリアル
  • 金ナノシェル
  • 金ナノロッド
  • 光熱治療・画像向け磁性金ナノシェル

第7章 診断用ナノデバイス・ナノマテリアル

  • 概要
  • 診断・医療装置産業
  • 結論・将来の動向

第8章 医療装置関連の感染向けナノマテリアルベースの治療

  • 医療装置関連の感染とその治療法
    • カテーテル関連の感染
    • 軟組織インプラント関連の感染
    • バイオフィルム(生物膜)形成
    • 一般的な予防・治療法
    • 医療用ナノマテリアル
  • 第9章 セラノスティック規制の枠組み
  • 概要

第10章 競合分析

  • イントロダクション
  • 請負製造業者
  • IT
  • 腫瘍学

第11章 企業パイプライン

第12章 治療・診断ガイドキット

第13章 特許状況

第14章 促進因子・阻害因子

第15章 企業プロファイル

図表

目次
Product Code: HLC144A

This report provides:

  • An overview of the global market for nanomaterials in medicine used for both therapy and diagnostics, or theranostics.
  • Analyses of global market trends, with data from 2011 and 2012, and projections of compound annual growth rates (CAGRs) through 2017.
  • Discussion of the advantages of nanoscale materials, such as in the fabrication of nano-machines that can deliver their cargo (a drug) to a precise location (for instance, the tumor tissue of a specific organ) so that healthy tissues are minimally affected, and in the fabrication of nano-drugs, diagnosis in vivo and therapeutic applications.
  • Examination of the role of theranostics in oncology, immunodeficiencies, and cardiovascular and neuro disorders.
  • Identification of the types of theranostic agents, such as gold-based, magnetic, polymeric, silica-based, carbon, composite, and lyposome nanomaterials.

SAMPLE FIGURE
GLOBAL THERANOSTIC NANOMATERIAL MARKET,
2011-2017 ($ MILLIONS)

Source: BCC Research

STUDY GOALS AND OBJECTIVE

This study provides a comprehensive analysis of the nanomaterial market for use in theranostics and personalized medicine. Theranostics is the fusion of therapy and diagnosis; it is the foundation of personalized medicine, which is a newly proposed model of highly customized healthcare. This study describes this model in detail and analyzes a large selection of nanomaterials that play various roles in the market, including proteins, monoclonal antibodies, nanoparticles, nanocrystals, liposomes and quantum dots.

This market is increasing exponentially in size and revenues, and it is changing the standards of the healthcare model, thus imposing new marketing tactics, strategic alliances, innovative business models and research and development (R&D) outsourcing paradigms.

This report addresses the drivers and limiters of this new model and offers an exhaustive analysis of the nanomaterials used in theranostics.

REASON FOR DOING THE STUDY

Theranostic and personalized medicine will be the ultimate transformation of modern healthcare to diagnose and treat diseases. Nanotechnology will be the toolbox used to execute this new approach to medicine. The report analyzes the market and includes historical sales of all the nanomaterials used in theranostics in 2011 and 2012. Sales are forecast through 2017.

This study in an invaluable instrument for understanding the ways in which the pharmaceutical and medical device markets are rapidly changing by forming new paradigms and marketing strategies. The market is characterized by the creation of partnerships, collaborations and mergers and acquisitions (M&A) between pharmaceutical companies, the medical device industries, academics and small startups. Seventeen new emerging geographic markets, including Russia, India, China, Turkey, South Africa and Thailand, are also discussed.

SCOPE OF THE REPORT

Blockbuster and one-size-fits-all drugs are slowly exiting the market to make room for the era of personalized medicine. Theranostics, which is the fusion of therapeutics and diagnostics, is the foundation of personalized medicine in which specific therapies are tailored to patients to treat diseases based on their genetic makeups and/or to determine which therapies will have the fewest side effects. Nanotechnology will play a pivotal role in this revolution, and the global market for nanomaterials used in theranostics will be more than $187 billion in 2017, increasing at a compound annual growth rate (CAGR) of 10.8%

Monoclonal antibodies will comprise the largest segment for the biologic nanomaterials, and liposome will be the largest segment for non-biologic nanomaterials. Other nanomaterials discussed in this report include fullerene C60, carbon nanotubes, quantum dots, gold nanoparticles and proteins.

Profiles of key market players and small startups are also included. Major products that generate the largest revenues, as well as the most-valuable R&D products that will come on the market up to 2017 are provided.

In-depth competitive market analysis is discussed, with examples of how new products will enter the market or how existing products will survive or perish. The report also includes a very detailed description of current and future technologies for the preparation of nanomaterials in theranostics.

ANALYST CREDENTIALS

Alessandro Varotto holds a Master's degree in Industrial Chemistry and a PhD in Chemistry with a specialty in Nanotechnology and Materials Science. Dr. Varotto has worked as a research scientist in both academic and industry environments. He is the author of 15 peer-reviewed research articles, a patent, a book and dozens of technical papers in the field of life science. His expertise includes chemistry and nanomaterials with medical applications.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY GOALS AND OBJECTIVE
  • REASON FOR DOING THE STUDY
  • SCOPE OF THE REPORT
  • INTENDED AUDIENCE
  • METHODOLOGY AND INFORMATION SOURCE
  • ANALYST CREDENTIALS
  • RELATED REPORTS
  • BCC ON-LINE SERVICES
  • DISCLAIMER

CHAPTER 2 - SUMMARY

  • SUMMARY TABLE: GLOBAL THERANOSTIC NANOMATERIAL MARKET, THROUGH 2017 ($ MILLIONS)
  • SUMMARY FIGURE: GLOBAL THERANOSTIC NANOMATERIAL MARKET, 2011-2017 ($ MILLIONS)

CHAPTER 3 - OVERVIEW

  • THERANOSTICS AND PERSONALIZED MEDICINE OVERVIEW
    • TABLE 1. THERAPIES WITH DIAGNOSTIC COMPANION KITS
    • FIGURE 1. RISK OF CANCER FOR PATIENTS THAT CARRY A SPECIFIC GENETIC MUTATION VS NON MUTATED (%)
  • NANOPARTICLES
  • PASSIVE TARGETING
  • ACTIVE TARGETING
  • NANOTECHNOLOGY OVERVIEW
  • NANOTECHNOLOGY PRODUCTS ON THE MARKET
  • SIZE DEFINITION
  • SHAPE
  • SURFACE AREA
  • QUANTUM DOTS
  • CARBON NANOTUBES
  • MULTIFUNCTIONAL NANOMATERIALS
    • TABLE 2. NANOMATERIAL TYPES
  • NANOTHERANOSTICS OVERVIEW
    • TABLE 3. MAJOR PLAYERS IN THE NANOPARTICLE DRUG FIELD
    • TABLE 4. NANOPARTICLE DRUG MARKET BY COMPANY, THROUGH 2017 ($ MILLIONS)
  • GOLD-BASED NANOMATERIALS
  • MAGNETIC NANOMATERIALS
  • POLYMERIC NANOMATERIALS
  • SILICA-BASED NANOMATERIALS
  • CARBON NANOMATERIALS
  • COMPOSITE NANOMATERIALS
  • BIOLOGIC NANOMATERIALS: ANTIBODY, PROTEINS AND DNA
  • OTHER NANOMATERIALS
  • DRUG DELIVERY
    • TABLE 5. MAJOR NANOMATERIAL APPLICATIONS IN THERANOSTICS

CHAPTER 4 - GLOBAL NANOMATERIAL THERANOSTICS MARKET

  • TABLE 6. GLOBAL NANOMATERIAL THERANOSTIC MARKET, THROUGH 2017 ($ MILLIONS)
  • FIGURE 2. TITLE GLOBAL NANOMATERIAL THERANOSTIC MARKET, 2011-2017 ($ MILLIONS)
  • GLOBAL MONOCLONAL ANTIBODIES IN THERANOSTICS MARKET
    • TABLE 7. GLOBAL MONOCLONAL ANTIBODY MARKET, THROUGH 2017 ($ MILLIONS)
    • TABLE 8. GLOBAL PROTEIN MARKET, THROUGH 2017 ($ MILLIONS)
  • GLOBAL REVENUES FROM NANOPARTICLES IN DIAGNOSTICS IMAGING SYSTEMS
    • TABLE 9. GLOBAL DIAGNOSTIC IMAGING AND TESTING NANOPARTICLE MARKET, THROUGH 2017 ($ MILLIONS)
  • GLOBAL REVENUES FOR DRUG DEVELOPMENT AND FORMULATION
    • TABLE 10. GLOBAL DRUG-DEVELOPMENT AND FORMULATION NANOPARTICLE MARKET, THROUGH 2017 ($ MILLIONS)
  • GLOBAL MAGNETIC RESONANCE IMAGING REAGENT MARKET
    • TABLE 11. GLOBAL IRON-OXIDE NANOPARTICLES USED AS MAGNETIC RESONANCE IMAGING CONTRAST AGENTS MARKET, THROUGH 2017 ($ MILLIONS)
  • GLOBAL IN VITRO OPTICAL IMAGING REAGENT MARKET
    • TABLE 12. GLOBAL NANOMATERIALS USED AS IN VITRO OPTICAL IMAGING REAGENTS MARKET, THROUGH 2017 ($ MILLIONS)
  • GLOBAL GOLD-BASED MATERIALS USED AS NANOCARRIERS MARKET
    • TABLE 13. GLOBAL GOLD-BASED NANOMATERIALS USED AS CARRIERS MARKET, THROUGH 2017 ($ MILLIONS)
  • GLOBAL LIPOSOMAL-BASED MATERIALS USED AS NANOCARRIERS MARKET
    • TABLE 14. GLOBAL LIPOSOME-BASED MATERIALS USED AS DRUG CARRIERS MARKET, THROUGH 2017 ($ MILLIONS)
  • GLOBAL NANOCRYSTAL DRUG MARKET
    • TABLE 15. GLOBAL NANOCRYSTAL DRUG MARKET, THROUGH 2017 ($ MILLIONS)
  • GLOBAL BLOCKBUSTER ANTIBODY DRUG MARKET
    • TABLE 16. GLOBAL MONOCLONAL ANTIBODY BLOCKBUSTER DRUG MARKET, THROUGH 2017 ($ MILLIONS)

CHAPTER 5 - NANOTHERANOSTIC DRUG DELIVERY

  • INTRODUCTION
  • IN VIVO DRUG RELEASE STUDIES
  • DRUG EFFICACY
  • FUTURE DIRECTIONS
    • TABLE 17. EXAMPLES OF NANOMATERIALS USED IN THERANOSTICS
    • TABLE 18. IMAGING MODALITIES USED IN THERANOSTIC NANODEVICES

CHAPTER 6 - NANOMATERIAL STRUCTURES, CHARACTERISTICS AND METHODS OF PREPARATION

  • CARBON NANOTUBES
  • CARBON NANOTUBES AS CARRIERS OF IMMUNOACTIVE COMPOUNDS, PROTEINS AND GENETIC MATERIALS
  • CANCER PHOTOTHERMAL THERAPY
  • CARBON NANOTUBES FOR OTHER THERAPEUTIC APPLICATIONS
  • FULLERENE C60
  • C60 TOXICITY
  • UPTAKE AND BIODISTRIBUTION
  • ANTIOXIDANT PROPERTIES
  • ENDOHEDRALS
  • MAGNETIC RESONANCE IMAGING
  • RADIONUCLIDES
  • PHOTODYANIMC THERAPY
  • DNA PHOTOCLEAVAGE
  • CANCER
  • INHIBITION OF ENZYMES, VIRUSES AND BACTERIA
  • DRUG AND GENE DELIVERY
  • PROTEINS
  • ENZYMES
    • TABLE 19. NON-MONOCLONAL ANTIBODY PROTEINS
  • MONOCLONAL ANTIBODIES
    • TABLE 20. MAJOR PLAYERS IN THE MONOCLONAL ANTIBODY MARKET
  • MONOCLONAL ANTIBODY THERAPY
    • TABLE 21. GLOBAL MONOCLONAL ANTIBODY MARKET
  • Mechanisms
  • NANOMATERIALS IN THERANOSTICS
    • TABLE 22. MAJOR PLAYERS IN NANOPARTICLE DRUG DEVELOPMENT
    • TABLE 23. NANOPARTICLE DRUG MARKET BY PRODUCT, THROUGH 2017
  • GOLD NANOPARTICLES
  • GOLD NANOCARRIERS
  • HYPERTHERMIA
  • CONTRAST ENHANCERS
  • RADIOTHERAPY
    • TABLE 24. U.S. FOOD AND DRUG ADMINISTRATION-APPROVED NANOPARTICLE DRUG-DELIVERY SYSTEMS
  • MAGNETIC NANOPARTICLES
  • HYPERTHERMIA
  • MAGNETIC SEPARATION
  • IMAGING AND DELIVERY
  • BRAIN TUMOR DELIVERY
  • PROSTATE CANCER
  • BLADDER TUMOR
  • LIPOSOMES
    • TABLE 25. LIPOSOME ADVANTAGES
  • LIPOSOME CLASSIFICATION AND PREPARATION
  • Sonication
  • Extrusion
  • Freeze-Thawed Liposomes
  • Solvent Dispersion Method
  • Detergent-Removal Method
  • STEALTH LIPOSOME
  • ANTIBODY-LIPOSOME CONJUGATE
  • Liposome Application in Medicine and Pharmacology
  • Liposomes in Parasitic Diseases and Infections
  • Liposomes in Anti-Cancer Therapies
    • TABLE 26. LIPOSOME-BASED DRUGS
    • TABLE 27. MAJOR PLAYERS IN THE LIPOSOME MARKET
  • NANOCRYSTALS
    • TABLE 28. NANOCRYSTAL PROPERTIES
    • TABLE 29. NANOCRYSTAL DRUG FEATURES
  • NANOCRYSTALS FABRICATION
    • TABLE 29. NANOCRYSTAL DRUG FEATURES
  • Precipitation Methods
  • Milling
  • Homogenization Method
    • TABLE 30. NANOCRYSTAL MANUFACTURING TECHNOLOGIES
    • TABLE 31. NANOCRYSTAL DRUGS CURRENTLY ON THE MARKET
  • QUANTUM DOTS
  • QUANTUM DOTS NANOCARRIER
  • PHOTOPHYSICAL PROPERTIES: DRUG-DELIVERY AND DRUG-RELEASE
  • SENSING
  • Visualizing Intracellular Uptake In Vitro
  • Nanocarrier Biodistribution In Vivo
  • Short Interfering RNA and DNA delivery
  • MULTIFUNCTIONAL NANOPARTICLES
  • POLYMERIC NANOPARTICLES IN CANCER THERAPY
  • Polymer-Based Imaging Probes for Cancer Imaging
  • QUANTUM DOTS IN CANCER IMAGING AND THERAPY
  • QUANTUM DOTS IN PHOTODYNAMIC THERAPY AND IMAGING
  • MULTIFUNCTIONAL MAGNETIC NANOPARTICLES FOR CANCER IMAGING AND THERAPY
  • MAGNETIC NANOPARTICLES FOR MAGNETIC RESONANCE IMAGING AND GENE DELIVERY
  • MULTIFUNCTIONAL MAGNETO-POLYMERIC NANOHYBRIDS FOR CANCER IMAGING AND THERAPY
  • GOLD NANOMATERIALS FOR PHOTOTHERMAL THERAPY
  • GOLD NANOSHELLS
  • GOLD NANORODS
  • MAGNETIC GOLD NANOSHELLS FOR PHOTOTHERMAL THERAPY AND IMAGING

CHAPTER 7 - NANODEVICES AND NANOMATERIALS FOR DIAGNOSTICS

  • OVERVIEW
  • MOLECULAR RECOGNITION IN DIAGNOSIS
  • NANOPATTERNED DEVICES
  • PARTICLES
  • Magnetic Nanoparticles
  • Quantum Dots
  • Aptamer-Conjugated Nanoparticles
  • Nanoparticle-Based Bio-Bar Codes
  • Multiplex Dendrimers
  • Surface Enhanced Raman Spectropscopy
  • DIAGNOSTIC AND MEDICAL DEVICE INDUSTRY
  • CONCLUSIONS AND FUTURE TRENDS
    • TABLE 32. KEY PLAYERS IN THE IN VITRO DIAGNOSTIC MARKET
    • TABLE 33. KEY PLAYERS IN THE DIAGNOSTIC IMAGING MARKET

CHAPTER 8 - NANOMATERIAL-BASED TREATMENTS FOR INFECTIONS ASSOCIATED WITH MEDICAL DEVICES

  • INFECTIONS ASSOCIATED WITH MEDICAL DEVICES AND THEIR TREATMENTS
  • CATHETER-ASSOCIATED INFECTIONS
  • SOFT-TISSUE-IMPLANT-ASSOCIATED INFECTIONS
  • BIOFILM FORMATION
  • COMMON METHODS FOR PREVENTING AND TREATING MEDICAL DEVICE-ASSOCIATED INFECTIONS
  • NANOMATERIALS IN MEDICAL APPLICATIONS
  • Antimicrobial Nanomaterials
  • Silver Nanoparticles
  • Zinc Oxide
  • Iron and Iron-Oxide Nanoparticles
  • Titanium Oxide
  • Carbon Nanotubes and Fullerenes
  • Chitosans
  • CYTOTOXICITY CONSIDERATION

CHAPTER 9 - THERANOSTIC REGULATORY FRAMEWORKS

  • OVERVIEW
  • NANOPRODUCT PHYSICOCHEMICAL PROPERTY DIFFERENCES COMPARED TO THEIR LARGER COUNTERPARTS
  • REGULATORY ISSUES IN NANOTECHNOLOGY

CHAPTER 10 - COMPETITIVE ANALYSIS

  • INTRODUCTION
  • CONTRACT MANUFACTURING ORGANIZATIONS
  • INFORMATION TECHNOLOGY
  • ONCOLOGY
    • TABLE 34. GLOBAL BLOCKBUSTER MONOCLONAL ANTIBODIES IN THE ONCOLOGY MARKET, THROUGH 2017 ($ MILLIONS)
    • TABLE 35. BLOCKBUSTER MONOCLONAL ANTIBODY PATENT EXPIRATION
  • BIOSIMILARS VERSUS GENERICS
  • Biosimilar: Competition and Improvement
  • ANTIRHEUMATICS MARKET
    • TABLE 36. BLOCKBUSTER MONOCLONAL ANTIBODIES FOR THE ANTIRHEUMATIC MARKET, THROUGH 2017
  • EMERGING MARKETS
    • TABLE 37. KEY PLAYERS IN THE GENERIC MARKET
    • TABLE 38. COMPANY EVENTS IMPACTING THE THERANOSTIC MARKET

CHAPTER 11 - COMPANY PIPELINES

  • TABLE 39. PROTEIN DRUGS
  • TABLE 40. NANOPARTICLES DRUGS

CHAPTER 12 - THERAPY AND DIAGNOSTICS COMPANION KITS

CHAPTER 13 - PATENT STATUS

  • TABLE 41. PATENTS BY TECHNOLOGY, 2001-2012
  • TABLE 42. QUANTUM DOT PATENT ASSIGNMENTS BY COMPANY
  • TABLE 43. GOLD NANOPARTICLE PATENT ASSIGNMENTS BY COMPANY

CHAPTER 14 - DRIVERS AND LIMITERS

  • DRIVERS
    • TABLE 44. THERANOSTIC MARKET DRIVERS
  • LIMITERS
    • TABLE 45. THERANOSTIC MARKET LIMITERS

CHAPTER 15 - COMPANY PROFILES

  • AFFYMETRIX
  • A.P. PHARMA INC.
  • ABRAXIS BIOSCIENCES INC.
  • PRODUCTS
  • ACUSPHERE INC.
  • PRODUCTS
  • STRATEGY
  • ACCUTHERANOSTICS
  • ADVANCED PROTEOME THERAPEUTICS INC.
  • ADVANCED RESEARCH TECHNOLOGIES INC.
  • PRODUCTS
  • STRATEGY
  • AFFIBODY AB
  • PRODUCTS
  • STRATEGY
  • AGENIX LTD.
  • PRODUCTS
  • STRATEGY
  • ALNYLAM PHARMACEUTICALS INC.
  • PRODUCTS
  • STRATEGY
  • ALSERES PHARMACEUTICALS INC.
  • PRODUCTS
  • STRATEGY
  • AMAG PHARMACEUTICALS INC.
  • PRODUCTS
  • STRATEGY
  • AMBRY GENETICS
  • APHIOS CORPORATION
  • PRODUCTS
  • STRATEGY
  • ALACRIS THERANOSTICS GMBH
  • ALZA CORP.
  • ARROWHEAD RESEARCH CORPORATION
  • PRIMARY OPPORTUNITIES
  • Improving Active Pharmaceutical Ingredients
  • Patient Population Enrichment Strategies
  • Improving Generics
  • LEAD PRODUCTS
  • PLATFORM TECHNOLOGIES
  • ASKLEPIOS BIOPHARMACEUTICAL INC.
  • PRODUCTS
  • STRATEGY
  • ASTELLA PAHRMA INC.
  • PRODUCTS
  • STRATEGY
  • ASTRAZENECA PHARMACEUTICALS PLC
  • PRODUCTS
  • STRATEGY
  • ATREUS PHARMACEUTICALS CORPORATION
  • PRODUCTS
  • STRATEGY
  • AXXAM SPA
  • BAYER HEALTHCARE AG
  • PRODUCTS
  • STRATEGY
  • BECKMAN COULTER
  • BIOMERIEUX
  • BIONKIT LTD.
  • BBI INTERNATIONAL
  • BIND BIOSCIENCES INC.
  • PRODUCTS
  • STRATEGY
  • BIOPAL
  • CERULEAN PHARMA INC.
  • PRODUCTS
  • STRATEGY
  • CYTIMMUNE
  • DEBIOTECH, S.A.
  • PRODUCTS
  • STRATEGY
  • ELAN PHARMACEUTICALS INC.
  • PRODUCTS
  • STRATEGY
  • EISAI
  • EPIGENOMICS AG
  • FLAMEL TECHNOLOGIES INC.
  • PRODUCTS
  • STRATEGY
  • FUJIFILM KYOWA KIRIN CO LTD.
  • GENOMIC HEALTH
  • GILEAD
  • GE GLOBAL RESEARCH
  • PRODUCTS
  • STRATEGY
  • GSK SMITHKLINE
  • INGEN BIOSCIENCES
  • INNOVA BIOSCIENCES
  • INSIGHT GENOMICS
  • IPSEN
  • IZON
  • JANSSEN BIOTECH INC.
  • JOHNSON & JOHNSON
  • LAB 21
  • LIQUIDIA TECHNOLOGIES INC.
  • MAGFORCE NANOTECHNOLOGIES AG
  • PRODUCTS
  • STRATEGY
  • MERCK
  • MONOGRAM BIOSCIENCES
  • NANOCS
  • NANOCARRIER CO. LTD.
  • PRODUCTS
  • STRATEGY
  • NANOCOMPOSIX
  • NANOPARTZ INC.
  • NANOPROBES INC.
  • NANOSPHERE INC.
  • PRODUCTS
  • STRATEGY
  • NANOSIGHT LTD.
  • NANOTHERAPEUTICS
  • NEKTAR
  • NOVARTIS INTERNATIONAL AG
  • PRODUCTS
  • STRATEGY
  • OCEAN NANOTECH
  • TECHNOLOGY
  • PACIFIC BIOMARKERS
  • PARTICLE SCIENCES
  • PFIZER
  • PHARNEXT
  • SANOFI
  • SELECTA BIOSCIENCE
  • SOLUBEST
  • SURMODICS INC.
  • SKYEPHARMA PLC
  • PRODUCTS
  • STRATEGY
  • STARPHARMA HOLDINGS LTD.
  • PRODUCTS
  • STRATEGY
  • T2 BIOSTEMS INC.
  • PRODUCTS
  • STRATEGY
  • TALON THERAPEUTICS INC.
  • PRODUCTS
  • STRATEGY
  • TAKEDA
  • THERANOSTIC HEALTH
  • PRECLINICAL BIOMARKER DISCOVERY
  • TRANSLATIONAL RESEARCH
  • PROTEOMIC TECHNOLOGIES
  • THERANOSTICS LAB LTD.

LIST OF TABLES

  • SUMMARY TABLE: GLOBAL THERANOSTIC NANOMATERIAL MARKET, THROUGH 2017 ($ MILLIONS)
    • TABLE 1: THERAPIES WITH DIAGNOSTIC COMPANION KITS
    • TABLE 2: NANOMATERIAL TYPES
    • TABLE 3: MAJOR PLAYERS IN THE NANOPARTICLE DRUG FIELD
    • TABLE 4: NANOPARTICLE DRUG MARKET BY COMPANY, THROUGH 2017 ($ MILLIONS)
    • TABLE 5: MAJOR NANOMATERIAL APPLICATIONS IN THERANOSTICS
    • TABLE 6: GLOBAL NANOMATERIAL THERANOSTIC MARKET, THROUGH 2017 ($ MILLIONS)
    • TABLE 7: GLOBAL MONOCLONAL ANTIBODY MARKET, THROUGH 2017 ($ MILLIONS)
    • TABLE 8: GLOBAL PROTEIN MARKET, THROUGH 2017 ($ MILLIONS)
    • TABLE 9: GLOBAL DIAGNOSTIC IMAGING AND TESTING NANOPARTICLE MARKET, THROUGH 2017 ($ MILLIONS)
    • TABLE 10: GLOBAL DRUG-DEVELOPMENT AND FORMULATION NANOPARTICLE MARKET, THROUGH 2017 ($ MILLIONS)
    • TABLE 11: GLOBAL IRON-OXIDE NANOPARTICLES USED AS MAGNETIC RESONANCE IMAGING CONTRAST AGENTS MARKET, THROUGH 2017 ($ MILLIONS)
    • TABLE 12: GLOBAL NANOMATERIALS USED AS IN VITRO OPTICAL IMAGING REAGENTS MARKET, THROUGH 2017 ($ MILLIONS)
    • TABLE 13: GLOBAL GOLD-BASED NANOMATERIALS USED AS CARRIERS MARKET, THROUGH 2017 ($ MILLIONS)
    • TABLE 14: GLOBAL LIPOSOME-BASED MATERIALS USED AS DRUG CARRIERS MARKET, THROUGH 2017 ($ MILLIONS)
    • TABLE 15: GLOBAL NANOCRYSTAL DRUG MARKET, THROUGH 2017 ($ MILLIONS)
    • TABLE 16: GLOBAL MONOCLONAL ANTIBODY BLOCKBUSTER DRUG MARKET, THROUGH 2017 ($ MILLIONS)
    • TABLE 17: EXAMPLES OF NANOMATERIALS USED IN THERANOSTICS
    • TABLE 18: IMAGING MODALITIES USED IN THERANOSTIC NANODEVICES
    • TABLE 19: NON-MONOCLONAL ANTIBODY PROTEINS
    • TABLE 20: MAJOR PLAYERS IN THE MONOCLONAL ANTIBODY MARKET
    • TABLE 21: GLOBAL MONOCLONAL ANTIBODY MARKET
    • TABLE 22: MAJOR PLAYERS IN NANOPARTICLE DRUG DEVELOPMENT
    • TABLE 23: NANOPARTICLE DRUG MARKET BY PRODUCT, THROUGH 2017
    • TABLE 24: U.S. FOOD AND DRUG ADMINISTRATION-APPROVED NANOPARTICLE DRUG-DELIVERY SYSTEMS
    • TABLE 25: LIPOSOME ADVANTAGES
    • TABLE 26: LIPOSOME-BASED DRUGS
    • TABLE 27: MAJOR PLAYERS IN THE LIPOSOME MARKET
    • TABLE 28: NANOCRYSTAL PROPERTIES
    • TABLE 29: NANOCRYSTAL DRUG FEATURES
    • TABLE 29: NANOCRYSTAL DRUG FEATURES
    • TABLE 30: NANOCRYSTAL MANUFACTURING TECHNOLOGIES
    • TABLE 31: NANOCRYSTAL DRUGS CURRENTLY ON THE MARKET
    • TABLE 32: KEY PLAYERS IN THE IN VITRO DIAGNOSTIC MARKET
    • TABLE 33: KEY PLAYERS IN THE DIAGNOSTIC IMAGING MARKET
    • TABLE 34: GLOBAL BLOCKBUSTER MONOCLONAL ANTIBODIES IN THE ONCOLOGY MARKET, THROUGH 2017 ($ MILLIONS)
    • TABLE 35: BLOCKBUSTER MONOCLONAL ANTIBODY PATENT EXPIRATION
    • TABLE 36: BLOCKBUSTER MONOCLONAL ANTIBODIES FOR THE ANTIRHEUMATIC MARKET, THROUGH 2017
    • TABLE 37: KEY PLAYERS IN THE GENERIC MARKET
    • TABLE 38: COMPANY EVENTS IMPACTING THE THERANOSTIC MARKET
    • TABLE 39: PROTEIN DRUGS
    • TABLE 40: NANOPARTICLES DRUGS
    • TABLE 41: PATENTS BY TECHNOLOGY, 2001-2012
    • TABLE 42: QUANTUM DOT PATENT ASSIGNMENTS BY COMPANY
    • TABLE 43: GOLD NANOPARTICLE PATENT ASSIGNMENTS BY COMPANY
    • TABLE 44: THERANOSTIC MARKET DRIVERS
    • TABLE 45: THERANOSTIC MARKET LIMITERS

LIST OF FIGURES

  • SUMMARY FIGURE: GLOBAL THERANOSTIC NANOMATERIAL MARKET, 2011-2017 ($ MILLIONS)
    • FIGURE 1: RISK OF CANCER FOR PATIENTS THAT CARRY A SPECIFIC GENETIC MUTATION VS NON MUTATED (%)
    • FIGURE 2: TITLE GLOBAL NANOMATERIAL THERANOSTIC MARKET, 2011-2017 ($ MILLIONS)
Back to Top